Agus ZS (2009)
Agus ZS, Berenson JR. Treatment of hypercalcemia. UpToDate, 2009.
Alsirafy SA (2009)
Alsirafy SA, Sroor MY, Al-Shahri MZ. Hypercalcemia in advanced head and neck squamous cell carcinoma: prevalence and potentiel impact on palliative care. Journal of Supportive Oncology 2009; 7: 154-157.
Body JJ (1989)
Body JJ, Magritte A, Seraj F et al. Aminohydroxypropylidene biphosphonate (APD) treatment for tumor-associated hypercalcemia: a randomized comparison between a 3-day treatment and single 24-hour infusions. Journal of Bone and Mineral Research 1989; 4: 923-928.
Body JJ (1994)
Body JJ, Dumon JC. Treatment of tumour-induced hypercalcemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type. Annals of Oncology 1994; 5: 359-363.
Body JJ (2000)
Body JJ, Louviaux I, Dumon JC. Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia. Supportive Care in Cancer 2000; 8: 398-404.
Body JJ (2004)
Body JJ. Hypercalcemia of malignancy. Seminars in Nephrology 2004; 24: 48-54.
Chevallier B (1988)
Chevallier B, Peyron R, Basuyau JP et al. Human calcitonin in neoplastic hypercalcemia. Results of a prospective randomized trial. Presse Medicale 1988; 17: 2375-2377.
Clines GA (2005)
Clines GA, Guise TA. Hypercalcemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocrine-Related Cancer 2005; 12: 549-583.
Dodwell DJ (1992)
Dodwell DJ, Howell A, Morton AR et al. Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcaemia. Postgraduate Medical Journal 1992; 68: 434-439.
Froelich A (1991)
Froelich A, McNair P, Transboel I. Awareness of hypercalcemia in a hospital population? Scandinavian Journal of Clinical and Laboratory Investigations 1991; 51: 37-41.
Grutters JC (1993)
Grutters JC, Hermus AR, Mulder de PH et al. Long-term follow up of breast cancer patients treated for hypercalaemia with aminohydroxypropylidene biphosphate (APD). Breast Cancer Research 1993; 25: 277- 281.
Gucalp R (1992)
Gucalp R, Ritch P, Wiernik PH et al. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. Journal of Clinical Oncology 1992; 10: 134-142.
Gucalp R (1994)
Gucalp R, Theriault R, Gill I et al. Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. Archives of Internal Medicine 1994; 154: 1935-1944.
Gurney H (1993)
Gurney H, Grill V, Martin TJ. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia. Lancet 1993; 341: 1611-1613.
Harinck HI (1987)
Harinck HI, Bijvoet OL, Plantingh AST et al. Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride. American Journal of Medicine 1987; 82: 1133-1142.
Horwitz MJ (2009)
Horwitz MJ. Hypercalcemia of malignancy. UpToDate, 2009.
Hosking DJ (1981)
Hosking DJ, Cowley A, Bucknall CA. Rehydration in the treatment of severe hypercalcaemia. Quarterly Journal of Medicine 1981; 50: 473-481.
Hosking DJ (1984)
Hosking DJ, Gilson D. Comparison of the renal and skeletal actions of calcitonin in the treatment of severe hypercalcaemia of malignancy. Quarterly Journal of Medicine 1984; 53: 359-368.
Lamy O (2001)
Lamy O, Jenzer-Closuit A, Burckhardt P. Hypercalcaemia of malignancy: an undiagnosed and undertreated disease. Journal of Internal Medicine 2001; 250: 73-79.
Leyvraz S (1992)
Leyvraz S, Hess U, Flesch G et al. Pharmacokinetics of pamidronate in patients with bone metastases. Journal of the National Cancer Institute 1992; 84: 788-792.
Ling PJ (1995)
Ling PJ, A’Hern RP, Hardy JR. Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD). British Journal of Cancer 1995; 72: 206-209.
Lumachi F (2009)
Lumachi F, Brunello A, Roma A et al. Cancer-induced hypercalcemia. Anticancer Research 2009; 29: 1551-1555.
Major P (2001)
Major P, Lortholary A, Hon J et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. Journal of Clinical Oncology 2001; 19: 558-567.
Morton AP (1988)
Morton AP, Cantrill JA, Craig AE et al. Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy. British Medical Journal 1988; 296: 811-814.
Nussbaum SR (1993)
Nussbaum SR, Younger J, Vandepol CJ et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60- and 90-mg dosages. American Journal of Medicine 1993; 95: 297-304.
O’Rourke NP (1993)
O’Rourke NP, McCloskey EV, Vasikaran S et al. Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate. British Journal of Cancer 1993; 67: 560-563.
Ostenstad B (1992)
Ostenstad B, Andersen OK. Disodium pamidronate versus mithramycin in the management of tumour-associated hypercalcemia. Acta Oncol. 1992;31(8):861-4.
Pecherstorfer M (1996)
Pecherstorfer M, Herrmann Z, Body JJ et al. Randomized phase II trial comparing different doses of the biphosphonate ibandronate in the treatment of hypercalcemia of malignancy. Journal of Clinical Oncology 1996; 14: 268-276.
Pecherstorfer M (2003)
Pecherstorfer M, Steinhauer EU, Rizzoli R et al. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. Supportive Care in Cancer 2003; 11: 539-547.
Penel N (2008)
Penel N, Dewas S, Doutrelant P et al. Cancer-associated hypercalcemia treated with intravenous diphosphonates: a survival and prognostic factor analysis. Supportive Care in Cancer 2008; 16: 387-392.
Penel N (2009)
Penel N, Dewas S, Hoffman A et al. Cancer-associated hypercalcemia: validation of a bedside prognostic score. Supportive Care in Cancer 2009; 17: 1133-1135.
Purohit OP (1995)
Purohit OP, Radstone CR, Anthony C at al. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. British Journal of Cancer 1995; 72: 1289-1293.
Ralston SH (1985)
Ralston SH, Gardner MD, Dryburgh FJ et al. Comparison of aminohydroxypropylidene diphosfonate, mithramycin and corticosteroids/calcitonin in the treatment of cancer-associated hypercalcaemia. Lancet 1985; 2: 907-910.
Ralston SH (1989)
Ralston SH, Gallacher SJ, Patel U et al. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia. Lancet 1989; 2: 1180-1182.
Ralston SH (1990)
Ralston SH, Gallacher SJ, Patel U et al. Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients. Annals of Internal Medicine 1990; 112: 499-504.
Ralston SH (1997)
Ralston SH, Thiebaud D, Hermann Z et al. Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. British Journal of Cancer 1997; 75: 295-300.
Roemer-Bécuwe C (2003)
Roemer-Bécuwe C, Vigano A, Romano F et al. Safety of subcutaneous clodronate and efficacy in hypercalcemia of malignancy: a novel route of administration. Journal of Pain and Symptom Management 2003; 26: 843-848.
Rotstein S (1992)
Rotstein S, Glas U, Eriksson M et al. Intravenous clodronate for the treatment of hypercalcaemia in breast cancer patients with bone metastases - a prospective randomised placebo-controlled multicentre study. European Journal of Cancer 1992; 28A: 890-893.
Saunders Y (2004)
Saunders Y, Ross JR, Broadley KE et al. Systematic review of bisphosphonates for hypercalcaemia of malignancy. Palliative Medicine 2004; 18: 418-431.
Sawyer N (1990)
Sawyer N, Newstead C, Drummond A et al. Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate (APD)) as single shot treatment of hypercalcaemia. Bone and Mineral 1990; 9: 121-128.
Stewart AF (2005)
Stewart AF. Clinical practice. Hypercalcemia associated with cancer. New England Journal of Medicine 2005; 352: 373-379.
Thiébaud D (1988)
Thiébaud D, Jaeger P, Jacquet AF et al. Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP. Journal of Clinical Oncology 1988; 6: 762-768.
Thiébaud D (1990)
Thiébaud D, Jacquet AF, Burckhardt P. Fast and effective treatment of malignant hypercalcemia. Combination of suppositories of calcitonin and a single infusion of 3-amino 1-hydroxypropylidene-1-bisphosphonate. Archives of Internal Medicine 1990; 150: 2125-2128.
Tyrrell CJ (1994)
Tyrrell CJ, Collinson M, Madsen EL et al. Intravenous pamidronate: infusion rate and safety. Annals of Oncology 1994; 5 (Suppl. 7): S27-S29.
Vassilopoulou-Sellin R (1993)
Vassilopoulou-Sellin R, Newman BM, Taylor SH et al. Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center. Cancer 1993; 71: 1309-1312.
Vaughn CB (1974)
Vaughn CB, Vaitkevicius VK. The effects of calcitonin in hypercalcemia in patients with malignancy. Cancer 1974; 34: 1268-1271.
Vinholes J (1997)
Vinholes J, Guo CY, Purohit OP et al. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy. Journal of Clinical Oncology 1997; 15: 131-138.
Walker P (1996)
Walker P, Watanabe S, Lawlor P et al. Subcutaneous clodronate. Lancet 1996; 348: 345-346.
Walker P (1997)
Walker P, Watanabe S, Lawlor P et al. Subcutaneous clodronate: a study evaluating efficacy in hypercalcemia of malignancy and local toxicity. Annals of Oncology 1997; 8: 915-916.
Walls J (1994)
Walls J, Ratcliffe WA, Howell A et al. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein. British Journal of Cancer 1994; 70: 169-172.
Wimalawansa SJ (1994)
Wimalawansa SJ. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate. Cancer 1994; 73: 2223-2230.
Wisneski LA (1990)
Wisneski LA. Salmon calcitonin in the acute management of hypercalcemia. Calcified Tissue International 1990; 46 (Suppl): S26-30.
De Wit S (1994)
De Wit S, Cleton FJ. Hypercalcemia in patients with breast cancer: a survival study. Journal of Cancer Research and Clinical Oncology 1994; 120: 610-614.